NCT01356290
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT01356290
Title Antiangiogenic Therapy for Children With Recurrent Medulloblastoma, Ependymoma, ATRT and Rare CNS Tumors (MEMMAT)
Acronym MEMMAT
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Medical University of Vienna
Indications
Therapies
Age Groups: adult | child
Covered Countries USA | SWE | NOR | FRA | ESP | DNK | CZE | AUT


No variant requirements are available.